Our members receive our quarterly e-newsletter with members-only content including interviews with dermatologists, information on contests and draws, and are the first to hear about upcoming events.

Membership is free.

Learn More

Special Access / Limited Use Designation Drugs

On most private or provincial drug programs, some medications may be listed as “special access” (SA) or “limited use” (LU) drugs or have Exceptional Drug Status (EDS).

Drugs with this designation are typically more expensive and require the fulfillment of certain criteria to be covered. Often, these criteria outline how severe one’s disease must be or what previous medications must have been taken before the drug plan will cover the special access or limited use medication.

It is worthwhile to check whether a drug is limited use or special access before you purchase it. You may otherwise risk not being reimbursed if the criteria have not been met.

Last updated July 24, 2020.


This Site was designed for educational purposes only and not for the purpose of rendering medical advice. Individual variances in psoriasis cases require the consultation of a physician to make sound medical decisions. The information presented on this website is not intended to replace the counsel of your physician. It is important to see your doctor before altering anything in your treatment plan. The Canadian Psoriasis Network does not endorse any medications, products, equipment or treatments for psoriasis and psoriatic arthritis. Any of the information contained within the Canadian Psoriasis Network’s Site is not presented as a substitute for informed medical advice. Visitors to this site should not engage in self-diagnosis nor act on information contained in the Site without seeking specific advice on the particular matters which are of concern to them from qualified health professionals and advisors. Some of the information contained in the Site has been provided from external sources. While efforts have been made to ensure the accuracy, currency, and reliability of the content, the Canadian Psoriasis Network accepts no responsibility in that regard. Please refer to our Terms of Use for further details.

This resource was made possible through support from:

LEO Pharma